TUSSICAPS 10mg/8mg CII
Generic Name and Formulations:
Hydrocodone bitartrate 10mg, chlorpheniramine maleate 8mg; as polistirex; ext–rel caps; contains alcohol.
Indications for TUSSICAPS 10mg/8mg:
Cough and upper respiratory symptoms.
1 cap (10mg/8mg) every 12hrs; max 2caps/24hrs.
<6yrs: see Contraindications. 6–11yrs: 1 cap (5mg/4mg) every 12hrs; max 2caps/24hrs.
Children <6yrs of age (risk of fatal respiratory depression).
Respiratory depression. Post–op. Pulmonary disease. Head injury. Increased intracranial pressure. Glaucoma. Asthma. GI or GU obstruction. Acute abdomen. Severe hepatic or renal impairment. Hypothyroidism. Addison's disease. Elderly. Debilitated. Labor & delivery. Pregnancy (Cat.C). Nursing mothers: not recommended.
Additive CNS depression with alcohol, other CNS depressants, tricyclic antidepressants, MAOIs. Paralytic ileus with concurrent anticholinergics.
Antitussive + antihistamine.
Nausea, vomiting, CNS and respiratory depression, ureteral and vesical sphincter spasm, chest tightness, abuse potential, anticholinergic effects, rash, pruritis.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Breast Cancer Screening Recommendations Not Completely Reflective of Race, Age
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|